Scientists test Next-Gen flu shot designed to fight more strains
NCT ID NCT06863142
Summary
This early-stage study is testing a new experimental flu vaccine called FluMos-v2. Researchers want to see if it's safe and how well it triggers an immune response in healthy adults, both by itself and when mixed with an experimental immune-boosting ingredient (ALFQ adjuvant). The study will enroll 45 participants who will receive two shots about four months apart and be followed for over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA PREVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.